Why Is SEAPORT THERAPEUTICS (SPTX) Stock Up Today?

Seaport Therapeutics (SPTX) rose 5.79% to $23.01 on Thursday, driven by positive Phase 1 trial results for its experimental drug GlyphAllo. The 33-volunteer study showed no driving impairment at 250 mg and met the primary endpoint at 375 mg, with no serious adverse events reported. The news, released within the last 36 hours, has drawn increased attention from analysts and investors.

What Happened

The company announced the positive topline results from its Phase 1 driving simulation trial of GlyphAllo in healthy volunteers. The trial, which was a key milestone in the drug’s development, showed no impairment at the 250 mg dose and met the primary endpoint at 375 mg. These findings were highlighted in multiple reports, including a presentation at Citigroup’s Biopharma Back to School Summit 2026. The BUOY-1 data, expected in the first half of 2027, will provide further insight into the drug’s potential. Analysts at Jones Trading and HC Wainwright & Co. have also expressed optimism, with the latter maintaining a $50 price target and a Buy rating.

What The Data Shows

SPTX opened at $21.58, a 0.8% gap down from the previous close, but climbed steadily throughout the session, reaching a high of $23.18 at 3:15 PM ET. The stock traded at 0.1M shares, below its average volume. The company has a market cap of $1.3B and remains unprofitable, with an EPS of -8.50 for the trailing twelve months. The stock has traded between $14.85 and $28.38 over the past 52 weeks. On September 10, SPTX printed nine fresh 52-week highs, reflecting growing investor interest. Additionally, insider Robert J. Hombach, a director, purchased shares on June 22, 2026, adding to recent insider buying activity totaling $236K in the last 90 days.

What To Watch

Investors should monitor the BUOY-1 data expected in early 2027, as well as the breadth of analyst coverage and any further updates on the GlyphAllo development timeline.